# US 2022/0031772 A1 · Compositions comprising bacterial strains

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031772 A1
- Document ID: US20220031772A1
- Status: Published application
- Kind: A1
- Application number: 17/231,247
- Filed: 2021-04-15
- Published: 2022-02-03
- Earliest claimed: 2018-10-19
- Assignees: 4D Pharma Research Limited
- Applicants: 4D Pharma Research Limited
- Inventors: Samantha YUILLE; Helene SAVIGNAC; Sarah REID; Imke Elisabeth MULDER; Nicole REICHARDT; Emma RAFTIS
- Web page: https://patentgrep.com/patent/US20220031772A1

## CPC

- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 11/06: Antiasthmatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- C12R 2001/145: Clostridium
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

The invention provides compositions comprising a bacterial strain of the species Blautia producta or Blautia coccoides, for use in therapy.

## Claims

### Claim at position 1

-15. (canceled)

### Claim 16

A method of treating one or more symptoms of a gastrointestinal inflammatory disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising a bacterial strain of the species Blautia producta or Blautia coccoides, wherein the bacterial strain comprises a 16s rRNA gene sequence having at least 95% sequence identity to SEQ ID NO: 1, wherein the one or more symptoms of the gastrointestinal inflammatory disease comprises ulcerations and/or bleeding, weight loss, poor weight gain, or increased gut permeability, and wherein the administering is effective to treat the one or more symptoms of the gastrointestinal inflammatory disease in the subject.

### Claim 17 (depends on 16)

The method of claim 16, wherein the gastrointestinal inflammatory disease comprises colitis, Crohn's disease, or inflammatory bowel disease (IBD).

### Claim 18 (depends on 17)

The method of claim 17, wherein the colitis comprises ulcerative colitis.

### Claim 19 (depends on 18)

The method of claim 18, wherein the ulcerative colitis comprises distal colitis, proctitis, proctosigmoiditis, left-sided colitis, extensive colitis, or pancolitis.

### Claim 20 (depends on 17)

The method of claim 17, wherein the Crohn's disease comprises Ileocolic Crohn's, Crohn's ileitis, or Crohn's colitis.

### Claim 21 (depends on 16)

The method of claim 16, wherein the administering is effective to reduce ulcerations and/or bleeding, reduce weight loss, enhance weight gain, or reduce gut permeability in the subject with the gastrointestinal inflammatory disease, thereby treating the gastrointestinal inflammatory disease.

### Claim 22 (depends on 16)

The method of claim 16, wherein the therapeutically effective amount comprises from about 1×103 to about 1×1011 colony forming units (CFU).

### Claim 23 (depends on 16)

The method of claim 16, wherein the composition comprises the bacterial strain in an amount from about 1×103 to about 1×1011 colony forming units per gram (CFU/g), with respect to the weight of the composition.

### Claim 24 (depends on 16)

The method of claim 16, wherein the bacterial strain is lyophilized.

### Claim 25 (depends on 16)

The method of claim 16, wherein the bacterial strain is viable and capable of partially or totally colonizing the intestine.

### Claim 26 (depends on 16)

The method of claim 16, wherein the composition comprises no more than de minimis or biologically irrelevant amounts of other bacterial strains or species.

### Claim 27 (depends on 16)

The method of claim 16, wherein the composition is encapsulated.

### Claim 28 (depends on 16)

The method of claim 16, wherein the administering comprises oral, rectal, subcutaneous, nasal, buccal, or sublingual administration.

### Claim 29 (depends on 16)

The method of claim 16, wherein the bacterial strain does not produce butyrate.

### Claim 30 (depends on 16)

The method of claim 16, wherein the bacterial strain comprises a 16s rRNA gene sequence that has at least 98% sequence identity to SEQ ID NO: 1.

### Claim 31 (depends on 16)

The method of claim 16, wherein the bacterial strain is the strain deposited under accession number NCIMB 43170, or a derivative or a biotype thereof.

### Claim 32

A pharmaceutical composition comprising a therapeutically effective amount of a bacterial strain of the species Blautia producta and a pharmaceutically acceptable excipient, diluent, or carrier;
wherein the bacterial strain is lyophilized;
wherein the therapeutically effective amount of the bacterial strain comprises from about 1×103 to about 1×1011 colony forming units per gram (CFU/g) with respect to the total weight of the pharmaceutical composition; and
wherein the bacterial strain comprises a 16s rRNA gene sequence of SEQ ID NO: 1

### Claim 33

A method of treating colitis in a subject with graft versus host disease (GVHD), comprising administering to the subject a therapeutically effective amount of a composition comprising a bacterial strain of the species Blautia producta or Blautia coccoides, wherein the bacterial strain comprises a 16s rRNA gene sequence having at least 95% sequence identity to SEQ ID NO: 1, and wherein the administering is effective to treat colitis in the subject with GVHD.

### Claim 34

A method of treating one or more symptoms associated with graft versus host disease (GVHD) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising a bacterial strain of the species Blautia producta or Blautia coccoides, wherein the bacterial strain comprises a 16s rRNA gene sequence having at least 95% sequence identity to SEQ ID NO: 1, wherein the one or more symptoms associated with GVHD comprises weight loss, poor weight gain, poor skin integrity, or increased gut permeability, and wherein the administering is effective to treat the one or more symptoms associated with GVHD in the subject.

### Claim 35

A method of treating an inflammatory or autoimmune disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising a bacterial strain of the species Blautia producta, wherein the bacterial strain comprises a 16s rRNA gene sequence of SEQ ID NO: 1.
